New signature predicts MBL-to-CLL progression

Richard Rosenquist
DOI: https://doi.org/10.1182/blood.2023023797
IF: 20.3
2024-04-26
Blood
Abstract:In this issue of Blood , Abdelbaky and colleagues report the development of a combined epigenetic and immunogenetic signature to study individuals with high-count monoclonal B-cell lymphocytosis (HC-MBL). 1 Using this signature, they define a new high-risk group with significantly increased likelihood of progression to chronic lymphocytic leukemia (CLL) compared with low-risk individuals.
hematology
What problem does this paper attempt to address?